Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 8.98 0.03 (0.34%) Market Cap: 1.29 Bil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 81/100

Aurinia Pharmaceuticals Inc Clinical Trial Update Transcript

Nov 02, 2020 / 09:30PM GMT
Release Date Price: $15.5 (-1.15%)
Operator

Hello, and welcome to the Aurinia Pharmaceuticals AUDREY update. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Glenn Schulman. Please go ahead, sir.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thank you, Kevin, and good afternoon, everyone. Welcome to this afternoon's conference call as we review the top line results of the AUDREY Phase II/III clinical study of VOS for the potential treatment of dry eye syndrome. Joining me from the Aurinia team on the call this afternoon are Mr. Peter Greenleaf, President and CEO; Dr. Neil Solomons, Chief Medical Officer; Mr. Mike Martin, Chief Business Officer; and Mr. Joe Miller, our Chief Financial Officer.

This afternoon, we issued the press release with the top line results from the AUDREY trial, which should be available on our website at www.auriniapharma.com. I'd like to remind everyone that today's call is being

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot